NZ754171A - Ectonucleotidase inhibitors and methods of use thereof - Google Patents
Ectonucleotidase inhibitors and methods of use thereofInfo
- Publication number
- NZ754171A NZ754171A NZ754171A NZ75417117A NZ754171A NZ 754171 A NZ754171 A NZ 754171A NZ 754171 A NZ754171 A NZ 754171A NZ 75417117 A NZ75417117 A NZ 75417117A NZ 754171 A NZ754171 A NZ 754171A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- amino
- dioxo
- compound
- dihydroanthracenesulfonate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437915P | 2016-12-22 | 2016-12-22 | |
| US201662437935P | 2016-12-22 | 2016-12-22 | |
| US201762555791P | 2017-09-08 | 2017-09-08 | |
| PCT/US2017/067980 WO2018119284A1 (en) | 2016-12-22 | 2017-12-21 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ754171A true NZ754171A (en) | 2022-12-23 |
Family
ID=62627279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ754171A NZ754171A (en) | 2016-12-22 | 2017-12-21 | Ectonucleotidase inhibitors and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10570167B2 (https=) |
| EP (1) | EP3558998A4 (https=) |
| JP (1) | JP7138351B2 (https=) |
| KR (1) | KR102638592B1 (https=) |
| CN (1) | CN110402249A (https=) |
| AU (1) | AU2017382888B2 (https=) |
| CA (1) | CA3047988A1 (https=) |
| IL (1) | IL267291B2 (https=) |
| MX (1) | MX383880B (https=) |
| NZ (1) | NZ754171A (https=) |
| TW (1) | TWI766923B (https=) |
| WO (1) | WO2018119284A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI767937B (zh) * | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| IL316357A (en) | 2017-07-31 | 2024-12-01 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| US12310965B2 (en) | 2019-03-29 | 2025-05-27 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| EP3982976A4 (en) * | 2019-06-14 | 2023-11-01 | Southern Research Institute | 2,4,7-SUBSTITUTED-7-DEAZA-2'-DEOXY-2'-FLUORARABINOSYL NUCLEOSIDE AND NUCLEOTIDE PRODRUGS AND USES THEREOF |
| KR20220024629A (ko) * | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
| JP7381913B2 (ja) * | 2021-10-13 | 2023-11-16 | ダイキン工業株式会社 | 有害生物防除組成物 |
| US12103943B2 (en) * | 2021-10-26 | 2024-10-01 | Southern Research Institute | Development of novel clofarabine analogs for cancer therapy |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2085994A1 (en) | 1991-04-24 | 1992-10-25 | Shinji Sakata | 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives |
| AU5449094A (en) | 1992-11-02 | 1994-05-24 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
| US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
| DE69531729T2 (de) * | 1994-12-13 | 2004-08-05 | Taiho Pharmaceutical Co. Ltd. | 3'-substuierte nukleosidderivate |
| NL1005244C2 (nl) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Oppervlakte-actieve aminen en glycosiden. |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| EP1860113A1 (en) * | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| WO2008011406A2 (en) | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| JP2011503084A (ja) | 2007-11-07 | 2011-01-27 | シェーリング コーポレイション | 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用 |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2590958B1 (en) | 2010-07-08 | 2015-08-26 | Life Technologies Corporation | In situ chemiluminescent substrates and assays |
| US20140154675A1 (en) | 2011-05-03 | 2014-06-05 | Life Technologies Corporation | Flash and Glow 1,2-Dioxetanes |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| WO2015164573A1 (en) * | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| HUE063388T2 (hu) * | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| TWI767937B (zh) | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
-
2017
- 2017-12-21 JP JP2019533622A patent/JP7138351B2/ja active Active
- 2017-12-21 CA CA3047988A patent/CA3047988A1/en not_active Abandoned
- 2017-12-21 WO PCT/US2017/067980 patent/WO2018119284A1/en not_active Ceased
- 2017-12-21 AU AU2017382888A patent/AU2017382888B2/en active Active
- 2017-12-21 US US15/851,166 patent/US10570167B2/en active Active
- 2017-12-21 KR KR1020197021200A patent/KR102638592B1/ko active Active
- 2017-12-21 MX MX2019007243A patent/MX383880B/es unknown
- 2017-12-21 NZ NZ754171A patent/NZ754171A/en unknown
- 2017-12-21 CN CN201780087047.8A patent/CN110402249A/zh active Pending
- 2017-12-21 EP EP17883974.2A patent/EP3558998A4/en not_active Withdrawn
- 2017-12-22 TW TW106145336A patent/TWI766923B/zh active
-
2019
- 2019-06-12 IL IL267291A patent/IL267291B2/en unknown
- 2019-12-19 US US16/720,369 patent/US11034715B2/en active Active
-
2021
- 2021-05-13 US US17/319,224 patent/US20230002437A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190114972A (ko) | 2019-10-10 |
| AU2017382888B2 (en) | 2021-12-23 |
| US11034715B2 (en) | 2021-06-15 |
| US20200223882A1 (en) | 2020-07-16 |
| IL267291B (en) | 2022-12-01 |
| IL267291B2 (en) | 2023-04-01 |
| CA3047988A1 (en) | 2018-06-28 |
| AU2017382888A1 (en) | 2019-06-20 |
| EP3558998A1 (en) | 2019-10-30 |
| JP7138351B2 (ja) | 2022-09-16 |
| JP2020504735A (ja) | 2020-02-13 |
| TW201834665A (zh) | 2018-10-01 |
| US10570167B2 (en) | 2020-02-25 |
| TWI766923B (zh) | 2022-06-11 |
| WO2018119284A1 (en) | 2018-06-28 |
| CN110402249A (zh) | 2019-11-01 |
| BR112019012327A2 (pt) | 2019-11-19 |
| US20180186827A1 (en) | 2018-07-05 |
| MX383880B (es) | 2025-03-14 |
| EP3558998A4 (en) | 2020-06-10 |
| US20230002437A1 (en) | 2023-01-05 |
| KR102638592B1 (ko) | 2024-02-19 |
| MX2019007243A (es) | 2019-09-06 |
| IL267291A (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ754171A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| JP2021529172A5 (https=) | ||
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| JP2020504735A5 (https=) | ||
| JP2019530669A5 (https=) | ||
| ES2991555T3 (es) | Composiciones y métodos para inhibir la actividad de la arginasa | |
| JP2016502544A5 (https=) | ||
| EP3267984B1 (en) | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators | |
| DK3041828T3 (en) | 1,3,4-OXADIAZOL AND 1,3,4-THIADIAZOLD DERIVATIVES AS IMMUNE MODULATORS | |
| EP3267993A1 (en) | Therapeutic cyclic compounds as immunomodulators | |
| JP2019524852A5 (https=) | ||
| JP2018510175A5 (https=) | ||
| HRP20220351T1 (hr) | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene | |
| ES2881048T3 (es) | Bisaminoquinolinas asimétricas y bisaminoquinolinas con enlazadores variados como inhibidores de la autofagia para el cáncer y otras terapias | |
| RU2018130330A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| CA2990192A1 (en) | Compositions and methods for inhibiting arginase activity | |
| CA2996681C (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
| DE69818041T2 (de) | Cyanoguanidine als zellproliferation inhibitoren | |
| JP2018529780A5 (https=) | ||
| RU2010133979A (ru) | Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов | |
| RU2003137007A (ru) | Новые пиридилцианогуанидиновые соединения | |
| US6372719B1 (en) | ανβ3 integrin antagonists in combination with chemotherapeutic agents | |
| JP2019526560A5 (https=) | ||
| JPWO2020257429A5 (https=) | ||
| JPWO2019246403A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ANTENGENE THERAPEUTICS LIMITED, CN Effective date: 20230116 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2024 BY CPA GLOBAL Effective date: 20231109 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251204 |